View Item 

Show simple item record

Measures of fibromyalgia: Fibromyalgia Impact Questionnaire (FIQ), Brief Pain Inventory (BPI), Multidimensional Fatigue Inventory (MFI‐20), Medical Outcomes Study (MOS) Sleep Scale, and Multiple Ability Self‐Report Questionnaire (MASQ)

dc.contributor.authorWilliams, David A.en_US
dc.contributor.authorArnold, Lesley M.en_US
dc.date.accessioned2011-12-05T18:35:21Z
dc.date.available2013-01-02T16:33:08Zen_US
dc.date.issued2011-11en_US
dc.identifier.citationWilliams, David A.; Arnold, Lesley M. (2011). "Measures of fibromyalgia: Fibromyalgia Impact Questionnaire (FIQ), Brief Pain Inventory (BPI), Multidimensional Fatigue Inventory (MFI‐20), Medical Outcomes Study (MOS) Sleep Scale, and Multiple Ability Self‐Report Questionnaire (MASQ)." Arthritis Care & Research 63(S11): S86-S97. <http://hdl.handle.net/2027.42/88107>en_US
dc.identifier.issn2151-464Xen_US
dc.identifier.issn2151-4658en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/88107
dc.publisherJohn Wiley & Sons, Inc.en_US
dc.titleMeasures of fibromyalgia: Fibromyalgia Impact Questionnaire (FIQ), Brief Pain Inventory (BPI), Multidimensional Fatigue Inventory (MFI‐20), Medical Outcomes Study (MOS) Sleep Scale, and Multiple Ability Self‐Report Questionnaire (MASQ)en_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelGeriatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan, Ann Arboren_US
dc.contributor.affiliationumChronic Pain & Fatigue Research Center, University of Michigan, 24 Frank Lloyd Wright Drive, Lobby M, Ann Arbor, MI 48106en_US
dc.contributor.affiliationotherUniversity of Cincinnati College of Medicine, Cincinnati, Ohioen_US
dc.identifier.pmid22588773en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/88107/1/20531_ftp.pdf
dc.identifier.doi10.1002/acr.20531en_US
dc.identifier.sourceArthritis Care & Researchen_US
dc.identifier.citedreferenceWolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken) 2010; 62: 600 – 10.en_US
dc.identifier.citedreferenceArnold LM, Crofford LJ, Mease PJ, Burgess SM, Palmer SC, Abetz L, et al. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns 2008; 73: 114 – 20.en_US
dc.identifier.citedreferenceMease PJ, Arnold LM, Crofford LJ, Williams DA, Russell IJ, Humphrey L, et al. Identifying the clinical domains of fibromyalgia: contributions from clinician and patient Delphi exercises. Arthritis Rheum 2008; 59: 952 – 60.en_US
dc.identifier.citedreferenceArnold LM, Mease PJ, Williams DA, Martin SA, Wang F, Emir B, et al. Development of responder definitions for fibromyalgia clinical trials. Arthritis Rheum 2010; 62: S38.en_US
dc.identifier.citedreferenceCella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, et al. The Patient‐Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self‐reported health outcome item banks: 2005‐2008. J Clin Epidemiol 2010; 63: 1179 – 94.en_US
dc.identifier.citedreferenceBennett RM. The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol 2005; 23: S154 – 62.en_US
dc.identifier.citedreferenceBurckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 1991; 18: 728 – 33.en_US
dc.identifier.citedreferenceBennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties. Arthritis Res Ther 2009; 11: R120.en_US
dc.identifier.citedreferenceWolfe F, Hawley DJ, Goldenberg DL, Russell IJ, Buskila D, Neumann L. The assessment of functional impairment in fibromyalgia (FM): Rasch analyses of 5 functional scales and the development of the FM Health Assessment Questionnaire. J Rheumatol 2000; 27: 1989 – 99.en_US
dc.identifier.citedreferenceArnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, et al. A randomized, double‐blind, placebo‐controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119: 5 – 15.en_US
dc.identifier.citedreferenceArnold LM, Russell IJ, Diri EW, Duan WR, Young JP Jr, Sharma U. A 14‐week, randomized, double‐blinded, placebo‐controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008; 9: 792 – 805.en_US
dc.identifier.citedreferenceArnold LM, Gendreau RM, Palmer RH, Gendreau JF, Wang Y. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double‐blind, placebo‐controlled trial. Arthritis Rheum 2010; 62: 2745 – 56.en_US
dc.identifier.citedreferenceArnold LM, Clauw DJ, Wohlreich MM, Wang F, Ahl J, Gaynor PJ, et al. Efficacy of duloxetine in patients with fibromyalgia: pooled analysis of 4 placebo‐controlled clinical trials. Prim Care Companion J Clin Psychiatry 2009; 11: 237 – 44.en_US
dc.identifier.citedreferenceBennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB. Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol 2009; 36: 1304 – 11.en_US
dc.identifier.citedreferenceCleeland CS. Measurement and prevalence of pain in cancer. Semin Oncol Nurs 1985; 1: 87 – 92.en_US
dc.identifier.citedreferenceDaut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983; 17: 197 – 210.en_US
dc.identifier.citedreferenceKeller S, Bann CM, Dodd SL, Schein J, Mendoza TR, Cleeland CS. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. Clin J Pain 2004; 20: 309 – 18.en_US
dc.identifier.citedreferenceTan G, Jensen MP, Thornby JI, Shanti BF. Validation of the Brief Pain Inventory for chronic nonmalignant pain. J Pain 2004; 5: 133 – 7.en_US
dc.identifier.citedreferenceDworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 2005; 113: 9 – 19.en_US
dc.identifier.citedreferenceWilliams VS, Smith MY, Fehnel SE. The validity and utility of the BPI interference measures for evaluating the impact of osteoarthritic pain. J Pain Symptom Manage 2006; 31: 48 – 57.en_US
dc.identifier.citedreferenceRadbruch L, Loick G, Kiencke P, Lindena G, Sabatowski R, Grond S, et al. Validation of the German version of the Brief Pain Inventory. J Pain Symptom Manage 1999; 18: 180 – 7.en_US
dc.identifier.citedreferenceMendoza T, Mayne T, Rublee D, Cleeland C. Reliability and validity of a modified Brief Pain Inventory short form in patients with osteoarthritis. Eur J Pain 2006; 10: 353 – 61.en_US
dc.identifier.citedreferenceCleeland C. The Brief Pain Inventory: user guide. Houston: MD Anderson Cancer Center; 2009.en_US
dc.identifier.citedreferenceFarrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL. Defining the clinically important difference in pain outcome measures. Pain 2000; 88: 287 – 94.en_US
dc.identifier.citedreferenceFarrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11‐point numerical pain rating scale. Pain 2001; 94: 149 – 58.en_US
dc.identifier.citedreferenceTurk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 2003; 106: 337 – 45.en_US
dc.identifier.citedreferenceMease PJ, Spaeth M, Clauw DJ, Arnold LM, Bradley LA, Russell IJ, et al. Estimation of minimum clinically important difference for pain in fibromyalgia. Arthritis Care Res (Hoboken) 2011; 63: 821 – 6.en_US
dc.identifier.citedreferenceDworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008; 9: 105 – 21.en_US
dc.identifier.citedreferenceSmets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995; 39: 315 – 25.en_US
dc.identifier.citedreferenceSmets EM, Garssen B, Cull A, de Haes JC. Application of the multidimensional fatigue inventory (MFI‐20) in cancer patients receiving radiotherapy. Br J Cancer 1996; 73: 241 – 5.en_US
dc.identifier.citedreferenceBarendregt PJ, Visser MR, Smets EM, Tulen JH, van den Meiracker AH, Boomsma F, et al. Fatigue in primary Sjogren's syndrome. Ann Rheum Dis 1998; 57: 291 – 5.en_US
dc.identifier.citedreferenceDekkers OM, Biermasz NR, Smit JW, Groot LE, Roelfsema F, Romijn JA, et al. Quality of life in treated adult craniopharyngioma patients. Eur J Endocrinol 2006; 154: 483 – 9.en_US
dc.identifier.citedreferenceJansen AJ, Essink‐Bot ML, Beckers EA, Hop WC, Schipperus MR, Van Rhenen DJ. Quality of life measurement in patients with transfusion‐dependent myelodysplastic syndromes. Br J Haematol 2003; 121: 270 – 4.en_US
dc.identifier.citedreferenceEricsson A, Mannerkorpi K. Assessment of fatigue in patients with fibromyalgia and chronic widespread pain: reliability and validity of the Swedish version of the MFI‐20. Disabil Rehabil 2007; 29: 1665 – 70.en_US
dc.identifier.citedreferenceFishbain DA, Lewis J, Cole B, Cutler B, Smets E, Rosomoff H, et al. Multidisciplinary pain facility treatment outcome for pain‐associated fatigue. Pain Med 2005; 6: 299 – 304.en_US
dc.identifier.citedreferenceLin JM, Brimmer DJ, Maloney EM, Nyarko E, Belue R, Reeves WC. Further validation of the Multidimensional Fatigue Inventory in a US adult population sample. Popul Health Metr 2009; 7: 18.en_US
dc.identifier.citedreferenceClauw DJ, Mease P, Palmer RH, Gendreau RM, Wang Y. Milnacipran for the treatment of fibromyalgia in adults: a 15‐week, multicenter, randomized, double‐blind, placebo‐controlled, multiple‐dose clinical trial. Clin Ther 2008; 30: 1988 – 2004.en_US
dc.identifier.citedreferenceHays RD, Stewart A. Sleep measures. In: Stewart A, Ware J, editors. Measuring functioning and well‐being: the medical outcomes study approach. Durham (NC): Duke University Press; 1992. p. 235 – 59.en_US
dc.identifier.citedreferenceMease PJ, Clauw DJ, Gendreau RM, Rao SG, Kranzler J, Chen W, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double‐blind, placebo‐controlled trial. J Rheumatol 2009; 36: 398 – 409.en_US
dc.identifier.citedreferenceHays RD, Martin SA, Sesti AM, Spritzer KL. Psychometric properties of the Medical Outcomes Study Sleep measure. Sleep Med 2005; 6: 41 – 4.en_US
dc.identifier.citedreferencePayne R, Mathias SD, Pasta DJ, Wanke LA, Williams R, Mahmoud R. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 1998; 16: 1588 – 93.en_US
dc.identifier.citedreferenceAllen RP, Kosinski M, Hill‐Zabala CE, Calloway MO. Psychometric evaluation and tests of validity of the Medical Outcomes Study 12‐item Sleep Scale (MOS sleep). Sleep Med 2009; 10: 531 – 9.en_US
dc.identifier.citedreferenceCoyne KS, Zhou Z, Bhattacharyya SK, Thompson CL, Dhawan R, Versi E. The prevalence of nocturia and its effect on health‐related quality of life and sleep in a community sample in the USA. BJU Int 2003; 92: 948 – 54.en_US
dc.identifier.citedreferenceWolfe F, Michaud K, Li T. Sleep disturbance in patients with rheumatoid arthritis: evaluation by medical outcomes study and visual analog sleep scales. J Rheumatol 2006; 33: 1942 – 51.en_US
dc.identifier.citedreferenceUnruh ML, Hartunian MG, Chapman MM, Jaber BL. Sleep quality and clinical correlates in patients on maintenance dialysis. Clin Nephrol 2003; 59: 280 – 8.en_US
dc.identifier.citedreferenceRejas J, Ribera MV, Ruiz M, Masrramon X. Psychometric properties of the MOS (Medical Outcomes Study) Sleep Scale in patients with neuropathic pain. Eur J Pain 2007; 11: 329 – 40.en_US
dc.identifier.citedreferenceCappelleri JC, Bushmakin AG, McDermott AM, Dukes E, Sadosky A, Petrie CD, et al. Measurement properties of the Medical Outcomes Study Sleep Scale in patients with fibromyalgia. Sleep Med 2009; 10: 766 – 70.en_US
dc.identifier.citedreferenceMartin S, Chandran A, Zografos L, Zlateva G. Evaluation of the impact of fibromyalgia on patients' sleep and the content validity of two sleep scales. Health Qual Life Outcomes 2009; 7: 64.en_US
dc.identifier.citedreferenceSeidenberg M, Haltiner A, Taylor MA, Hermann BB, Wyler A. Development and validation of a Multiple Ability Self‐Report Questionnaire. J Clin Exp Neuropsychol 1994; 16: 93 – 104.en_US
dc.identifier.citedreferenceBanos JH, LaGory J, Sawrie S, Faught E, Knowlton R, Prasad A, et al. Self‐report of cognitive abilities in temporal lobe epilepsy: cognitive, psychosocial, and emotional factors. Epilepsy Behav 2004; 5: 575 – 9.en_US
dc.identifier.citedreferenceMartin R, Griffith HR, Sawrie S, Knowlton R, Faught E. Determining empirically based self‐reported cognitive change: development of reliable change indices and standardized regression‐based change norms for the multiple abilities self‐report questionnaire in an epilepsy sample. Epilepsy Behav 2006; 8: 239 – 45.en_US
dc.identifier.citedreferenceDonovan KA, Small BJ, Andrykowski MA, Schmitt FA, Munster P, Jacobsen PB. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early‐stage breast carcinoma. Cancer 2005; 104: 2499 – 507.en_US
dc.identifier.citedreferenceJim HS, Donovan KA, Small BJ, Andrykowski MA, Munster PN, Jacobsen PB. Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer 2009; 115: 1776 – 83.en_US
dc.identifier.citedreferenceWilliams DA, Clauw DJ, Glass JM. Perceived cognitive dysfunction in fibromyalgia syndrome. J Musculoskelet Pain 2011; 19: 66 – 75.en_US
dc.identifier.citedreferenceOwen RT. Milnacipran hydrochloride: its efficacy, safety and tolerability profile in fibromyalgia syndrome. Drugs Today (Barc) 2008; 44: 653 – 60.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
20531_ftp.pdf
Size:
112.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.